Controversies in Pediatric and Adolescent Hematology
A. E. Thomas, C. Halsey
- 196 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
Controversies in Pediatric and Adolescent Hematology
A. E. Thomas, C. Halsey
About This Book
Hematological disorders in children and adolescents pose a wide range of management challenges and treatment dilemmas. In this book an internationally acclaimed panel of authors, each chosen for expertise in their field, have produced a state-of-the-art collection of review articles focusing on the very latest advances and controversies in the management of pediatric and adolescent hematological problems. The whole range of benign and malignant, congenital and acquired, acute and chronic conditions is discussed in detail. Individual chapters cover hematologic problems on the pediatric intensive care unit, treatments for iron deficiency and ITP; advances in stem cell transplantation, gene therapy, novel pharmaceutics and molecular diagnostics, as well as transition from child to adult are also explored. Providing an up-to-date look at both specific hematologic disorders in the pediatric and adolescent population and also hematologic problems that arise in association with systemic disease, this book is essential reading not only for pediatric and adult hematologists but also for pediatricians, pediatric or hematologic specialist nurse practitioners and pediatric pharmacologists.
Frequently asked questions
Information
Pediatr Adolesc Med. Basel, Karger, 2014, vol 17, pp 42-66 (DOI: 10.1159/000350346)
Hematological Problems in Pediatric Intensive Care
Abstract
Disorders of Red Blood Cells
Anemia
a RBC transfusion |
Key points |
Suggested transfusion ‘triggers’ |
- A hemoglobin transfusion threshold of 70 g/l can decrease RBC transfusion requirement without an increase in adverse outcome |
Strategies to reduce RBC transfusion requirements |
- Limit blood sampling for laboratory testing to that essential for the wellbeing of the child |
RBC transfusion in children with SCD |
- Simple or exchange RBC transfusions for arterial ischemic stroke, acute chest syndrome, multiorgan failure, splenic sequestration, perioperative, aplastic crisis |
- Exchange (not simple) transfusion is recommended if the baseline hemoglobin level is >90 g/l and/or if a rapid decrease in HbS level to below 30% is required |
Pediatric dose: 10-15 ml/kg of packed RBCs (10 ml/kg for units stored in CPDA-1, otherwise, 15 ml/kg for AS-1, AS-3, AS-5, SAGM units). In children >20 kg body weight the transfusion volume is rounded to the nearest number of packed RBC units. |
b Granulocyte transfusion |
Key points |
Granulocyte transfusions are rarely used in children |
Clinical efficacy of granulocyte transfusion is still uncertain/controversial |
Hematology/transfusion medicine consultation is recommended if granulocyte transfusion is |
being considered in children with severe neutropenia who satisfy all of the following criteria: |
- Very severe neutropenia (absolute neutrophil counts <0.2 × 109/l) due to congenital or acquired bone marrow failure unresponsive to G-CSF therapy |
- Proven or highly probable fungal or bacterial infection unresponsive to appropriate anti-infective therapy |
- Neutrophil recovery expected within the near future and/or definitive or curative therapy (e.g. hematopoietic stem cell transplantation) is planned |
Pediatric dose: ‘buffy coat’ preparation 10-20 ml/kg or apheresis granulocyte concentrate - 1 unit. All granulocyte preparations must be irradiated before transfusion. |
c Platelet transfusion |
Key points |
Suggested prophylactic platelet transfusion ‘triggers’ for thrombocytopenia due to production failure |
- In most cases a threshold of 10 × 109/l is safe and cost-effective |
- Threshold of 20 × 109/l in neonates, in children with sepsis, and children with a higher bleeding risk (e.g. children with underlying bleeding disorders) |
- Threshold of 30 × 109/l for children with brain tumors |
- Threshold of 50 × 109/l for children requiring lumbar puncture, surgery |
- Threshold of 100 × 109/l for children requiring neurosurgical procedures |
Platelet refractoriness |
- Defined as an inadequate rise in platelet counts as measured within 10 min to 1 h of a transfusion of an adequate number of platelets |
Pediatric dose: 10-15 ml/kg or 1 U whole blood-derived platelets/per 10 kg body weight, up to the equivalent of 1 U of apheresis platelet or 5-6 U of whole blood-derived platelets. |
d Frozen plasma and cryoprecipitate transfusion |
Key points |
For confirmed congenital factor deficiencies |
- Specific recombinant factor concentrate (or virally inactivated plasma derived concentrate if former not available) |
Indications for frozen plasma |
- For deficiency of factors II, V, VII, IX, X, XI when recombinant or plasma-derived, virus-inactivated factor concentrates are not available |
- For multiple factor deficiencies (e.g. liver failure) associated with severe bleeding |
- For DIC with active bleeding, prior to an invasive procedure and/or significant multiple factor deficiencies |
- For reversal of VKA (e.g. Warfarin) anticoagulation effect for patients who are actively bleeding or who require emergency surgery (PCC are licensed for this indication and may be used if readily available) |
Pediatric dose: Frozen plasma: 15-20 ml/kg to a maximum of 3-4 U (the standard dose is 4 U of 250 ml for a 70-kg adult and 3 Units of 250 ml for a 50-kg adult) |
Indications for cryoprecipitate |
- May be used when specific factor concentrates are unavailable for deficiency of factors VIII, von Willebrand factor, fibrinogen |
- Fibrinogen level of <0.5 g/l in the setting of a child who is not actively bleeding or <1.0 g/l in an actively bleeding child or one in whom an invasive procedure is planned |
Pediatric dose: Cryoprecipitate: 1 U per 7-10 kg, to a maximum of 10 U. |
SCD = Sickle cell disease; CPDA = citrate phosphate dextrose adenine; AS = additive solution; SAGM = saline adenine glucose mannitol; G-CSF = granulocyte-colony stimulating factor. |